FDA issues major rebuke to CytoDyn over claims on Covid-19 drug – STAT
The agency’s conclusions undercut the claims made by CytoDyn when one of its clinical trials read out in early March.
The agency’s conclusions undercut the claims made by CytoDyn when one of its clinical trials read out in early March.
Covid wreaked havoc on the world. It also provided an unprecedented look at the human immune system.
If the U.S. does not develop a coherent industrial policy for the life sciences, they may play second fiddle to advances being made in other…
Washington is cracking down on the technology running behind the scenes in health care following the debilitating Change Healthcare cyberattack.
Researchers say oligosaccharides, or sugars in human milk, could help repair gut microbiome and boost immunity in immunocompromised patients.
This week on “The Readout LOUD” podcast: Who gets to sue the FDA? Is pharma caught in a trade war? And what does “AF” stand…
The financial ties between drug and device makers and some physicians remains pervasive, according to a new analysis.
Check out the inaugural edition of Adam’s Biotech Scorecard, a new newsletter from @statnews.
Join STAT’s leading DC bureau as they take the stage with policymakers, patient advocates, and industry experts to discuss the biggest issues in health policy…
Could the FDA ban certain decaf coffees? Advocates want to strip out a chemical in the brew.
“This is not about, ‘O.K., let’s not use GLP-1s’ or anything. It’s just about, ‘let’s be careful when you’re doing procedures on these patients.’”